Comparative Pharmacology
Head-to-head clinical analysis: EPIFOAM versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIFOAM versus HC 1.
EPIFOAM vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
Unknown
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect.
2–4 hours (terminal); prolonged in renal impairment.
Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine.
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid